Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
60 participants
INTERVENTIONAL
2019-05-01
2022-08-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Dexmedetomidine Supplemented Analgesia and Incidence of Postoperative Delirium
NCT03012984
Intraoperative Sedatives and Postoperative Deilirium
NCT03251651
Dexmedetomidine and Long-term Outcome in Elderly Patients After Surgery
NCT02809937
Effect of Dexmedetomidine on Postoperative Delirium Inflammasome Activation Inhibition
NCT03588988
Dexmedetomidine and 5-year Outcome in Elderly Patients After Surgery
NCT03436472
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
We hypothesized postoperative dexmedetomidine for two days as a mixture drug of fentanyl-based PCA could reduce the incidence of postoperative delirium. We compared this effect with other control group who received fentanyl-based PCA only.
We also investigate EEG patterns of patients during emergence and compared the EEG patterns who developed delirium postoperatively in PACU(Postanesthesia care unit) or general ward. Dexmedetomidine has analgesic effect. We expected postoperative dexmedetomidine has benefits of opioid sparing effects.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
dexmedetomidine group
dexmedetomidine mixture with fentanyl-based PCA infusion for 2 days
Dexmedetomidine
dexmedetomidine 0.5 micg/kg/hr infusion during operation and followed by 0.2 mic/kg/hr with fentanyl-based PCA mixture for 2 days
Fentanyl-based PCA infusion
Fentanyl-based PCA infusion
control group
Fentanyl-based PCA infusion for 2 days
Fentanyl-based PCA infusion
Fentanyl-based PCA infusion
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Dexmedetomidine
dexmedetomidine 0.5 micg/kg/hr infusion during operation and followed by 0.2 mic/kg/hr with fentanyl-based PCA mixture for 2 days
Fentanyl-based PCA infusion
Fentanyl-based PCA infusion
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Exclusion Criteria
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Korea University Guro Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Il Ok Lee
professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Il-Ok Lee, professor
Role: STUDY_CHAIR
Korea University Guro Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
KoreaUniversity Guro Hospital
Seoul, Guro-ku, South Korea
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
K2019-03 58-003
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.